Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.

Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial

Silk SE. et al, (2024), The Lancet Infectious Diseases

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.

Datoo MS. et al, (2024), Lancet (London, England), 403, 533 - 544

Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults

Silk SE. et al, (2023), Med, 4, 668 - 686.e7

Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination

Minassian AM. et al, (2021), Med, 2, 701 - 719.e19

Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies

Folegatti PM. et al, (2021), Vaccines, 9, 262 - 262

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.

Wilkie M. et al, (2020), Vaccine, 38, 779 - 789

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine

Folegatti PM. et al, (2019), Vaccines, 7, 40 - 40

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal

Venkatraman N. et al, (2019), The Journal of Infectious Diseases, 219, 1187 - 1197

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.

Manjaly Thomas Z-R. et al, (2019), PLoS medicine, 16

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line

Folegatti PM. et al, (2019), Vaccines, 7, 33 - 33

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children

Tiono AB. et al, (2018), PLOS ONE, 13, e0208328 - e0208328

Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP

Bliss CM. et al, (2018), Scientific Reports, 8

Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells

Jin J. et al, (2018), npj Vaccines, 3

Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP

Rampling T. et al, (2018), npj Vaccines, 3

Prime and target immunization protects against liver-stage malaria in mice

Gola A. et al, (2018), Science Translational Medicine, 10, eaap9128 - eaap9128

Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A

Wajja A. et al, (2018)

Corrigendum to “Heterologous Two-dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-lasting Cellular Immunity to Influenza Virus A in Healthy Adults” [EBioMedicine 29 (2018) 146–154]

Coughlan L. et al, (2018), EBioMedicine, 31, 321 - 321

Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults

Coughlan L. et al, (2018), EBioMedicine, 29, 146 - 154

"PRIME-TARGET" IMMUNIZATION WITH VIRAL VECTORS FOR ENHANCED EFFICACY OF LIVER-STAGE MALARIA VACCINES

Ewer K. et al, (2018), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 99, 585 - 585

Load More

1
2
3
4
5

Include forthcoming?